Home / Resource Library / Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

Real world study of CAR-T Brexucabtagene autoleucel for treatment of relapsed MCL.